Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?

Yılmaz, Hikmet; Çakmak, Muzaffer; İnan, Osman; Darçın, Tahir; Akçay, Ali

doi:10.1007/s40618-014-0222-2

Cited by 75 publications

(64 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The obtained results substantiate the study of Seferovic et al, [28] which describes elevated levels of Gal-3 in patients with type 2 DM that were strongly correlated with HbA1c levels. Yilmaz et al [29] showed that Gal-3 may be an independent predictor of type 2 DM in general. Recent clinical studies have shown that high levels of Gal-3 correlate with gender, age, and the risk of cardiovascular pathology development.…”

Section: [27]mentioning

confidence: 99%

Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

Bobronnikova¹

2017

View full text Add to dashboard Cite

How to cite this article: Bobronnikova L. Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes. Vessel Plus 2017;1:61-7. Aim:To determine the impact of galectin-3 levels on the progression of metabolic disorders and structural-functional changes in the myocardium and blood vessels in patients with concomitant systemic arterial hypertension (AH) and type 2 diabetes mellitus (type 2 DM). Methods: Ninety-five patients with hypertension stage II grade 2 (53 males and 42 females) were examined. The patients were separated: group 1 (n = 32) patients with AH, without carbohydrate metabolism disorders; group 2 (n = 30) patients with AH and pre-diabetes; group 3 (n = 33) concomitant AH and type 2 DM. Carbohydrate metabolism, insulin resistance parameters and galectin-3 levels were measured. Echocardiography was performed to determine the structural-functional condition of the heart. Estimation of the intima-media complex thickness of the common carotid artery was performed by duplex ultrasound scanning. Results: Hypertrophy of the left ventricular myocardium is most evident in patients with AH and type 2 DM compared with groups 1 and 2, and the control group (P < 0.05). The levels of galectin-3 in the group with concomitant hypertension and type 2 DM were higher than in groups 1 and 2, and the control group (P < 0.05). A positive correlation was revealed between the level of galectin-3, indices of insulin resistance, and structural-functional cardiac and vessel remodeling. Conclusion: Galectin-3 levels in serum are significantly linked with indices of insulin resistance and cardiovascular remodeling. Key words:Arterial hypertension, type 2 diabetes mellitus, insulin resistance, cardiovascular remodeling, galectin-3 ABSTRACTArticle history:

show abstract

Section: [27]mentioning

confidence: 99%

Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

Bobronnikova¹

2017

View full text Add to dashboard Cite

show abstract

“…В проведенном нами исследовании средний уро-вень галектина-3 в группе пациентов с МС оказался достоверно выше по сравнению с группой без МС (1,89±1,71 нг/мл против 1,03±0,22 нг/мл, р=0,006), что согласуется с результатами других клинических исследований, доступных в настоящее время [6][7][8].…”

Section: таблица 2 сравнительные характеристики по данным эхокг и допunclassified

“…Подобная зависимость прослеживалась в исследовании под руко-водством Lisowska (2016), в котором галектин-3 показал себя независимым фактором риска возникновения ИБС [5]. Вместе с тем, в ряде исследований установлено повышение уровня галектина-3 у пациентов с ожире-нием [6], с предиабетом и диабетом [7], а также у паци-ентов с фибрилляцией предсердий и МС [8].…”

unclassified

GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE

Драпкина¹,

Shepel²,

Деева³

2017

Russ J Cardiol

View full text Add to dashboard Cite

30Cердечно-сосудистые заболевания (ССЗ) по-прежнему продолжают занимать лидирующие пози-ции среди причин смертности в Российской Федера-ции. Согласно последним данным, на долю смертно-сти от ишемической болезни сердца (ИБС) приходится 46,8%, что мотивирует ученых и клини-цистов к поиску новых и совершенствованию имею-щихся методов ранней диагностики и эффективного лечения различных форм этой патологии [1].В то же время, все чаще обсуждается проблема метаболического синдрома (МС) и его влияния при полиморбидной патологии. Эксперты Всемирной ОЦЕНКА УРОВНЯ ГАЛЕКТИНА-3 У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ И ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА Aim.To assess the level of galectin-3 in blood serum of patients with metabolic syndrome (MS), including comorbidity with coronary heart disease (CHD), for evaluation of its significance as fibrosis marker in MS. material and methods. Totally, 43 MS patients studied with CHD signs, and 33 patients non-MS of comparable age, of those CHD was diagnosed in 17. Mean age in MS group was 62,7±10,3 y. o. at baseline, in controls (non-MS) -60±14,7 y. o. Galectin-3 level was measured via immune-enzyme assay on "Platinum ELISA". Results. Mean level of galectin-3 in MS group was significantly higher and reached 1,89±1,71 ng/mL, comparing to non-MS group -1,03±0,22 ng/mL (р=0,006). There were positive correlations of galectin-3 and CHD functional class by NYHA (r=0,346, р=0,012): in absence of CHD signs galectin-3 level was 1,05±0,26 ng/mL; in CHD of 1 functional class (FC) -1,06±0,18 ng/mL; 2 FC -1,7±1,59 ng/mL; 3 FC -2,15±1,85 ng/mL. Conclusion.The level of fibrosis marker galectin-3 are higher in MS patients than in non-MS, and in MS+CHD is higher than in those without this pathology. Finding of high level of galectin-3 in MS and CHD patients might witness on the severity of myocardial fibrosis, supporting prognosis.

show abstract

“…Według Yilmaz i wsp. gal-3 może brać udział w progresji stanu przedcukrzycowego do cukrzycy i w związku z tym może stać się obiecującym markerem zaburzeń gospodarki węglo-wodanowej i ryzyka rozwoju cukrzycy wykorzystywanym we wczesnej diagnostyce [40].…”

Section: Galektynaunclassified

Significance of selected inflammatory factors in metabolic disorders in association with psoriasis

Kiluk¹,

Baran²,

Flisiak³

2017

View full text Add to dashboard Cite

Increased levels of galectin-3 were associated with prediabetes and diabetes: new risk factor?

Abstract: Gal-3 is a promising biomarker for detecting prediabetes and diabetes.

Cited by 75 publications

References 33 publications

Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

Galectin-3 as a potential biomarker of metabolic disorders and cardiovascular remodeling in patients with hypertension and type 2 diabetes

GALECTIN-3 LEVEL IN pATIENTS WITH mETAbOLIC SYNDROmE AND CORONARY HEART DISEASE

Significance of selected inflammatory factors in metabolic disorders in association with psoriasis

Contact Info

Product

Resources

About